Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454)- R8 - Effective September 26, 2024

Date Posted: September 26, 2024

This Local Coverage Article (LCA) has been revised under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: September 26, 2024

Summary of Changes:

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to read "muscle-invasive bladder". This revision is due to new covered test that has successfully completed a TA and is effective for 4/19/2022.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to add "ovarian". This revision is due to new covered test that has successfully completed a TA and is effective for 12/14/2023.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to add "(neoadjuvant)". This revision is due to new covered test that has successfully completed a TA and is effective for 12/20/2023.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #2 to add "in patients with a personal history of cancer" and "Natera". Formatting was corrected throughout the article. This revision is due to covered test that has successfully completed a TA and is effective for 5/12/2022.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs  or access it via the CMS MCD.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )